Endologix Inc.

299 articles with Endologix Inc.

• Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sept. 16, 2019

  9/16/2019

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced the grant of inducement equity awards to two newly hired employees.

• Endologix Announces Exclusive Distributor Agreement with Boston Scientific for the Chinese Market

  8/8/2019

  The long-term agreement includes distribution rights to Endologix’s current EndoVascular Aneurysm Repair and Endovascular Aneurysm Sealing products, as well as the right of first negotiation for future product offerings by Endologix.

• Endologix Reports Second Quarter 2019 Financial Results

  8/8/2019

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced financial results for the second quarter ended June 30, 2019.

• Endologix, Inc. to Announce Second Quarter 2019 Financial Results on August 8, 2019

  7/15/2019

  Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the second quarter of fiscal year 2019 after the market close on Thursday, August 8, 2019.

• Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 11, 2019

  7/11/2019

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced the grant of inducement equity awards to three newly hired employees.

• Endologix, Inc. to Present at the BMO Prescriptions for Success Healthcare Conference

  6/17/2019

  Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John Onopchenko, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the 2019 BMO Prescriptions for Success Healthcare Conference

• Endologix Announces Reinstatement of CE Mark for its Nellix EndoVascular Aneurysm Sealing System

  6/6/2019

  Endologix® Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the EC Certificate of Conformity (CE Mark) for the Nellix EndoVascular Aneurysm Sealing System (Nellix System) has been reinstated by GMED, the EU Notified Body for the Nellix System.

• Endologix Reports First Quarter 2019 Financial Results

  5/2/2019

  Today announced financial results for the first quarter ended March 31, 2019.

• Endologix, Inc. to Announce First Quarter 2019 Financial Results on May 2, 2019

  4/15/2019

  Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2019 after the market close on Thursday, May 2, 2019.

• Endologix Announces Equity Financing of $52 Million and Debt Restructuring Addressing 2020 Maturities and Financial Covenants

  4/1/2019

  The Company reports preliminary revenue for the first quarter ending March 31, 2019 of at least $35 million

• Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - March 20, 2019

  3/20/2019

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced the grant of inducement equity awards to nine newly hired employees.

• Endologix Announces Approval of Reverse Stock Split

  3/5/2019

  Endologix, Inc. previously announced that a proposal was approved at its Special Meeting of Stockholders, held February 22, 2019, authorizing its Board of Directors to amend the Company's certificate of incorporation.

• Endologix Reports Fourth Quarter and Fiscal Year 2018 Financial Results

  2/25/2019

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced financial results for the fourth quarter and fiscal year ended December 31, 2018.

• Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  2/11/2019

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced the grant of inducement equity awards to eight newly hired employees.

• Endologix, Inc. to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on February 25, 2019

  1/29/2019

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced that it will report financial results for the fourth quarter and fiscal year 2018 after the market close on Monday, February 25, 2019.

• Endologix Provides Update on Previously Announced Voluntary Nellix System Recall

  1/22/2019

  Endologix Inc.®  (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the EC Certificate of Conformity (CE Mark) for the Nellix EndoVascular Aneurysm Sealing System (Nellix System) has been suspended by its Notified Body, GMED, following a voluntary recall and Field Safety Notification (FSN) issued by Endologix on January 4, 2019.

• Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) on December 10, 2018

  1/11/2019

  Endologix, Inc. announced today the grant of inducement equity awards to a newly hired executive (the “Awardee”).

• Endologix Appoints John D. Zehren as Chief Commercial Officer

  1/10/2019

  Endologix, Inc. (Nasdaq:ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed John D. Zehren as the Company’s Chief Commercial Officer, effective as of January 7, 2019 (the “Effective Date”).

• Endologix Announces Fourth Quarter and Full-Year 2018 Preliminary Financial Results and Provides 2019 Financial Guidance

  1/7/2019

  Endologix, Inc. (the “Company”) (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the fourth quarter ended December 31, 2018 is expected to be approximately $34 million.

• Endologix Takes Decisive Action to Optimize Patient Outcomes by Ensuring Nellix System Used Only within Current Indications

  1/4/2019

  Endologix® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today that in order to ensure optimal outcomes for patients, unrestricted sales and use of the Nellix System will cease immediately, and the product will only be available for use under clinical protocol with pre-screened patients that adhere to the current indications.